RT Journal
A1 Carroll BJ
T1 SUicide risk and efficacy of antidepressant drugs
JF JAMA Psychiatry
JO JAMA Psychiatry
YR 2013
FD January 1
VO 70
IS 1
SP 123
OP 125
DO 10.1001/jamapsychiatry.2013.756
UL http://dx.doi.org/10.1001/jamapsychiatry.2013.756
AB 
These conclusions are unsound. The data are contaminated by trial LYAQ,2- 4 which studied atomoxetine hydrochloride with or without fluoxetine in patients with attention-deficit/hyperactivity disorder with depressive or anxious symptoms. Less than half had major depression diagnoses4; pretreatment depression scores matched posttreatment scores in the other youth studies.2 These problematic details were not addressed. By lack of conforming diagnoses and design, LYAQ outright invalidates the aggregate analyses.